Oxurion NV
Research Oxurion NV (OXUR) on Bullrun: market cap EUR 248.34K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOXUR
- ExchangeBR
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 248.34K
- Financial periodFY2025
- RevenueEUR 555.00K
- Revenue growth18400.0%
- Net income-EUR 3.73M
- Free cash flow-EUR 1.71M
- Gross margin100.0%
Valuation Snapshot
latest market cap is EUR 248.34K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 555.00K | -EUR 3.73M | -EUR 1.71M | 100.0% | -0.13 | EUR 430.00K | EUR 11.44M | -EUR 12.89M |
| FY2024 | EUR 3.00K | EUR 119.00K | -EUR 2.07M | -1333.3% | 0 | EUR 455.00K | EUR 11.33M | -EUR 11.06M |
| FY2023 | EUR 263.00K | -EUR 18.97M | -EUR 9.77M | 39.5% | -114.82 | EUR 1.62M | EUR 12.33M | -EUR 13.19M |
| FY2022 | EUR 595.00K | -EUR 31.69M | -EUR 19.44M | 13.8% | -3700 | EUR 3.50M | EUR 8.02M | -EUR 4.58M |
| FY2021 | EUR 1.13M | -EUR 29.16M | -EUR 27.01M | 45.7% | -7700 | EUR 9.74M | EUR 12.10M | -EUR 1.08M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 248.34K | n/a | n/a | n/a |
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines for vascular retinal disorder in Belgium. The company is developing ophthalmic treatments to preserve vision for patients geographic atrophy and wet age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Oxurion NV's market cap?
Oxurion NV's market capitalization is EUR 248.34K.
What does Oxurion NV do?
Oxurion NV, a biopharmaceutical company, develops medicines for vascular retinal disorder in Belgium. The company is developing ophthalmic treatments to preserve vision for patients geographic atrophy and wet age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.